ORG Wealth Partners LLC Takes $91,000 Position in Sanofi (NASDAQ:SNY)

ORG Wealth Partners LLC purchased a new stake in shares of Sanofi (NASDAQ:SNY) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,667 shares of the company’s stock, valued at approximately $91,000.

A number of other hedge funds and other institutional investors have also modified their holdings of SNY. Price T Rowe Associates Inc. MD raised its holdings in shares of Sanofi by 88.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock valued at $522,991,000 after purchasing an additional 5,091,304 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Sanofi in the 4th quarter valued at $135,933,000. Boston Partners grew its stake in Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after buying an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC grew its stake in Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after buying an additional 1,705,148 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Sanofi by 969.6% in the 4th quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company’s stock valued at $45,850,000 after buying an additional 861,770 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ SNY opened at $47.86 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The firm has a market capitalization of $117.37 billion, a price-to-earnings ratio of 17.09, a P/E/G ratio of 0.98 and a beta of 0.50. The company’s fifty day moving average is $51.23 and its two-hundred day moving average is $52.00. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. The company had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The business’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period last year, the business posted $1.78 EPS. Equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were given a dividend of $2.0369 per share. This is a positive change from Sanofi’s previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date was Friday, May 9th. Sanofi’s payout ratio is 57.14%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. BNP Paribas assumed coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price on the stock. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research note on Monday, June 2nd. Guggenheim reiterated a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Hsbc Global Res upgraded shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.